Let’s Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

As an FDA-mandated rule goes into effect requiring healthcare providers to notify women of their breast density, the American Cancer Society has an explainer on what the rule means for patients and providers.

Analysis of another dataset of patients treated with CAR T-cell therapy showed a 5.2% incidence of secondary cancers within 1 year. (Epic Research)

A survivor of advanced breast cancer has turned her experience into a documentary film. (Cedars-Sinai)

Results of a small clinical study suggested that piano lessons for cancer patients might help alleviate treatment-related “brain fog.” (U.S. News & World Report)

Johnson & Johnson announced discontinuation of a phase III trial of intravesical extended-release gemcitabine (TAR-200) plus cetrelimab versus chemoradiation for muscle-invasive bladder cancer after an interim analysis showed no difference in bladder-intact event-free survival.

Merck announced that a phase III trial of perioperative pembrolizumab (Keytruda) combined with adjuvant radiation therapy (with or without chemotherapy) for resectable head and neck squamous cell cancer met the primary endpoint of improved event-free survival versus adjuvant radiation therapy (with or without chemotherapy) alone.

Pfizer announced that a phase III trial of talazoparib (Talzenna) plus enzalutamide (Xtandi) met the primary endpoint of improved overall survival in metastatic castration-resistant prostate cancer compared with enzalutamide alone.

Commonly used breast cancer therapies — including chemotherapy, radiation, and surgery — increase production of biomarkers associated with biological aging. (UCLA Health Jonsson Comprehensive Cancer Center, Journal of the National Cancer Institute)

A 3D-printed breast prosthesis may be able to detect and inhibit tumor recurrence. (Advanced Science)

Should increased reliance on industry funding for clinical trials in cancer be cause for concern? (UNC Lineberger Comprehensive Cancer Center, Journal of Clinical Oncology)

A husband-and-wife cancer research team in Iran has come under scrutiny over published research involving cancer cell lines that allegedly were not available through the national cell bank. (Retraction Watch)

A blood test for circulating tumor cells reliably predicted response to treatment and prognosis in men with metastatic hormone-sensitive prostate cancer. (USC Keck School of Medicine, JAMA Network Open)

Please enable JavaScript to view the comments powered by Disqus.